Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platforms to potential new drug candidates is therefore very uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; (vi) if Nektar is unable to establish and maintain collaboration partnerships on attractive commercial terms (such as for NKTR-102), our business, results of operations and financial condition could suffer; and (vii) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed with the SEC on July 28, 2010, the Current Report on Form 8-K filed with the SEC today, and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 to be filed with the SEC on or about November 4, 2010.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics(650) 631-4954Susan Noonan/SA Noonan Communications, LLC(212) 966-3650Nektar Media Inquiries: Karen Bergman/BCC Partners(650) 575-1509 Michelle Corral/BCC Partners(415) 794-866
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... LONDON , July 29, 2014 ... 2014 Global Frost & Sullivan Best Practices Award ... solution is a cloud-based platform that connects digital ... - such as providers, pharmaceutical companies, prevention and ... electronics. Each year, Frost & ...
(Date:7/29/2014)... , July 29, 2014   Health 2.0 ... a keynote alongside visionary physicians Eric Topol , ... at the Health 2.0 8th Annual Fall Conference ... This year, Health 2.0 is set to host ... of the larger session on Consumer Tech & Wearables: ...
(Date:7/28/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... webcast to discuss financial results for the second quarter of ... 2014 at 4:30 p.m. ET. Conference call ... 2014 Time: 4:30 PM ET Listen via Internet: http://ir.pharmacyclics.com/events.cfm ... A webcast replay will be available on the Pharmacyclics website ...
Breaking Medicine Technology:Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2
... Inc. (OTC Bulletin Board: WGBS ), a leading developer ... an overview of the company at the 13th annual BIO CEO ... Hotel, Tuesday, February 15, 2011 at 11:30 a.m. Eastern time.  The ... may be accessed at www.wafergen.com . The BIO ...
... Caliper Life Sciences, Inc. (Nasdaq: CALP ) ... protocols on its Sciclone® NGS Workstation for Illumina,s TruSeq™ ... In addition to the automation protocols for TruSeq kits, ... library preparation kits, as well as for Agilent,s SureSelect™ ...
Cached Medicine Technology:WaferGen to Present at 13th Annual BIO CEO and Investor Conference 2Caliper Life Sciences Announces Availability of Automated TruSeq™ Next Generation Sequencing Protocols 2
(Date:7/29/2014)... This Latest Guidebook for Conducting Pharma Clinical Trials ... only provided a comprehensive and thorough knowledge of the ... registration but also introduced the practical operation how to ... use the Chinese trial venues to keep drug development ... step. , The audiences of this guidebook are overseas ...
(Date:7/29/2014)... controversy over how best to treat patients after they,ve ... until the cancer comes back or provide men with ... a new study from Thomas Jefferson University ... patients make a more informed decision. , "We are ... author Robert Den, M.D., Assistant Professor of Radiation Oncology ...
(Date:7/29/2014)... principle suitable to find out which preferences patients have ... health economic evaluations, some (primarily methodological) issues still need ... pilot project by the German Institute for Quality and ... Process (AHP), CA is the second method tested by ... outcome-specific results to an overall value , In ...
(Date:7/29/2014)... repeatedly shown that death rates rise in association with ... in the summer of 2003, for example, resulted in ... by Dr. Alex-andra Schneider at the Institute of Epidemiology ... of extreme temperatures on the number of deaths caused ... both high and low temperatures in the study. , ...
(Date:7/29/2014)... stressful situations better than others, and it,s not ... differences in how they respond. , Researchers have ... of genetically identical mice that predicts how well ... , The findings, published July 29 in ... potential consequences of chronic stress -- such as ...
Breaking Medicine News(10 mins):Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Genomic analysis of prostate cancer indicates best course of action after surgery 2Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4Health News:Mortality rates increase due to extreme heat and cold 2Health News:A new brain-based marker of stress susceptibility 2
... 26 Concentric Medical, Inc., the global leader in ... announced that the company,s Merci Retrieval System(TM) has been ... August 2004. The Merci Retrieval System is a ... remove blood clots from patients suffering an ischemic stroke. ...
... Group at Frost & Sullivan is ... Presentation on the European Orphan Diseases Market to ... 2 p.m. GMT.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )Today,s pharmaceutical companies ... market because of the patent expiry of blockbuster ...
... of advanced health screening solutions in local communities, announces the deployment ... make the investment in the new unit in response to increased ... to increased capacity requirements related to the company,s planned geographical expansion ... ...
... Inc. anticipates growth and expansion of telemedicine services to include ... mental health centers. , ... N. ... continues to advance, regulations pertaining to hospital and physician reimbursement ...
... tumor characteristics that may help indicate which breast cancer patients ... to remove the unaffected breast. Published in the March ... of the American Cancer Society, the study could help patients ... diagnosed with breast cancer are known to be at increased ...
... procedure to remove the unaffected breast in breast cancer patients ... patients who have high-risk features as assessed by examining the ... to researchers at The University of Texas M. D. Anderson ... 1, 2009 issue of Cancer , may help physicians ...
Cached Medicine News:Health News:Concentric Medical Reaches Important Stroke Milestone 2Health News:Concentric Medical Reaches Important Stroke Milestone 3Health News:Frost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters - An Attractive Future? 2Health News:HealthYes! Announces Deployment of a New Mobile Health Screening Unit 2Health News:HealthYes! Announces Deployment of a New Mobile Health Screening Unit 3Health News:A Newly Approved CMS Medicare Package Expands Reimbursement Coverage for Telehealth Originating Sites Beginning January 1, 2009 2Health News:Study examines risk factors for cancer in unaffected breast of breast cancer patients 2Health News:Researchers identify risk factors for contralateral breast cancer 2
... eyewear and sunwear, inspired by ... personal style, with long lasting ... the collection include sophistication, elegance ... offer clean modern shapes, classic ...
... designs with children in mind, making eyewear ... stay-put cable temples. Its not surprising that ... as the best selling childrens collection from ... popular is its ability to keep pace ...
... The Calvin Klein Collection. Provocatively inspired ... - a bold outlook. Innovative structure: ... Modern technology enhances modern design. Technological ... and enhance the face., ,The Calvin ...
Inquire...
Medicine Products: